Law360, New York (August 13, 2007, 12:00 AM EDT) -- Following a June ruling that AstraZeneca, Bristol-Myers Squibb and Schering-Plough Corp. had inflated average wholesale prices for drugs, the pharmaceutical companies have asked that final judgment regarding damages be rendered posthaste so they can file a swift appeal.
In a motion filed Friday in the U.S. District Court for the District of Massachusetts, the companies said that when Judge Patti B. Saris makes her final determination on damages, “the matter will be ripe for appeal.”
A judge has scheduled a hearing on damages for Aug. 27....
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.